• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

奥司他韦治疗流感样症状患者的下呼吸道并发症风险：十一项随机临床试验的荟萃分析。

Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials.

机构信息

Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.

出版信息

Clin Infect Dis. 2011 Aug 1;53(3):277-9. doi: 10.1093/cid/cir400. Epub 2011 Jun 15.

DOI:10.1093/cid/cir400
PMID:21677258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3137795/
Abstract

An independent reanalysis of 11 randomized clinical trials shows that oseltamivir treatment reduces the risk of lower respiratory tract complications requiring antibiotic treatment by 28% overall (95% confidence interval [CI], 11%-42%) and by 37% among patients with confirmed influenza infections (95% CI, 18%-52%).

摘要

一项对 11 项随机临床试验的独立重新分析表明，奥司他韦治疗总体上降低了需要抗生素治疗的下呼吸道并发症风险 28%（95%置信区间 [CI]，11%-42%），在确诊流感感染的患者中降低了 37%（95% CI，18%-52%）。

相似文献

1
Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials.奥司他韦治疗流感样症状患者的下呼吸道并发症风险：十一项随机临床试验的荟萃分析。
Clin Infect Dis. 2011 Aug 1;53(3):277-9. doi: 10.1093/cid/cir400. Epub 2011 Jun 15.
2
Does oseltamivir really reduce complications of influenza?奥司他韦真的能降低流感并发症的发生率吗？
Clin Infect Dis. 2011 Dec;53(12):1302-3; author reply 1303-4. doi: 10.1093/cid/cir706.
3
Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study.奥司他韦早期治疗对确诊 2009 年甲型 H1N1 流感住院患者的益处：回顾性队列研究。
J Antimicrob Chemother. 2011 May;66(5):1150-5. doi: 10.1093/jac/dkr089. Epub 2011 Mar 9.
4
Oseltamivir effect on antibiotic-treated lower respiratory tract complications in virologically positive randomized trial participants.在病毒学检测呈阳性的随机试验参与者中，奥司他韦对抗生素治疗的下呼吸道并发症的影响。
Clin Infect Dis. 2013 Nov;57(9):1368-9. doi: 10.1093/cid/cit481. Epub 2013 Jul 24.
5
Antiviral drugs in influenza: an adjunct to vaccination in some situations.流感抗病毒药物：在某些情况下作为疫苗接种的辅助手段。
Prescrire Int. 2006 Feb;15(81):21-30.
6
Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes.奥司他韦与糖尿病患者流感相关并发症及住院风险
Clin Ther. 2007 Oct;29(10):2246-55. doi: 10.1016/j.clinthera.2007.10.001.
7
Comparative efficacy assessment of antiviral alone and antiviral-antibiotic combination in prevention of influenza-B infection associated complications.单独抗病毒与抗病毒-抗生素联合治疗预防乙型流感感染相关并发症的疗效比较评估。
Expert Rev Anti Infect Ther. 2021 Sep;19(9):1165-1173. doi: 10.1080/14787210.2021.1889369. Epub 2021 Mar 5.
8
Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials.神经氨酸酶抑制剂在减少流感并发症方面的有效性和安全性：一项随机对照试验的荟萃分析。
J Antimicrob Chemother. 2010 Jul;65(7):1330-46. doi: 10.1093/jac/dkq158. Epub 2010 May 20.
9
Comparing intravenous peramivir with oral oseltamivir for patients with influenza: a meta-analysis of randomized controlled trials.比较帕拉米韦静脉注射与奥司他韦口服治疗流感患者的疗效：一项随机对照试验的荟萃分析。
Expert Rev Anti Infect Ther. 2021 Aug;19(8):1039-1046. doi: 10.1080/14787210.2021.1878025. Epub 2021 Mar 1.
10
Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials.奥司他韦治疗成人流感：随机对照试验的荟萃分析。
Lancet. 2015 May 2;385(9979):1729-1737. doi: 10.1016/S0140-6736(14)62449-1. Epub 2015 Jan 30.

引用本文的文献

1
Prevalence and healthcare burden of inappropriate antimicrobial treatment in patients at high risk of complications from acute respiratory infections: a scoping review.急性呼吸道感染并发症高危患者不适当抗菌治疗的患病率及医疗负担：一项范围综述
Front Med (Lausanne). 2025 May 16;12:1533797. doi: 10.3389/fmed.2025.1533797. eCollection 2025.
2
Impact of Oseltamivir and Diabetes Development.奥司他韦与糖尿病发病的关联
Pharmaceuticals (Basel). 2025 Jan 18;18(1):128. doi: 10.3390/ph18010128.
3
Impact of antiviral therapy on short- and long-term outcomes of patients with chronic obstructive pulmonary disease after influenza infection.抗病毒治疗对流感感染后慢性阻塞性肺疾病患者短期和长期结局的影响。
Influenza Other Respir Viruses. 2023 Dec 13;17(12):e13231. doi: 10.1111/irv.13231. eCollection 2023 Dec.
4
Optimizing antiviral treatment for seasonal influenza in the USA: a mathematical modeling analysis.优化美国季节性流感的抗病毒治疗：一项数学建模分析。
BMC Med. 2021 Mar 1;19(1):54. doi: 10.1186/s12916-021-01926-5.
5
Seasonal and pandemic influenza: 100 years of progress, still much to learn.季节性流感和大流行性流感：百年进展，仍有许多未知。
Mucosal Immunol. 2020 Jul;13(4):566-573. doi: 10.1038/s41385-020-0287-5. Epub 2020 Apr 21.
6
Seasonal Human Influenza: Treatment Options.季节性人类流感：治疗选择
Curr Treat Options Infect Dis. 2014;6(3):227-244. doi: 10.1007/s40506-014-0019-z. Epub 2014 Jun 25.
7
Influenza-associated mortality in hospital care: a retrospective cohort study of risk factors and impact of oseltamivir in an English teaching hospital, 2016 to 2017.2016 至 2017 年在一家英国教学医院中开展的一项回顾性队列研究：流感相关医院死亡率、危险因素以及奥司他韦的影响。
Euro Surveill. 2019 Oct;24(44). doi: 10.2807/1560-7917.ES.2019.24.44.1900087.
8
Update: Influenza Activity - United States and Worldwide, May 19-September 28, 2019, and Composition of the 2020 Southern Hemisphere Influenza Vaccine.更新：2019 年 5 月 19 日至 9 月 28 日美国和全球的流感活动情况，以及 2020 年南半球流感疫苗的组成。
MMWR Morb Mortal Wkly Rep. 2019 Oct 11;68(40):880-884. doi: 10.15585/mmwr.mm6840a3.
9
Statins and outcomes of hospitalized patients with laboratory-confirmed 2017-2018 influenza.他汀类药物与 2017-2018 年实验室确诊流感住院患者结局的关系。
Eur J Clin Microbiol Infect Dis. 2019 Dec;38(12):2341-2348. doi: 10.1007/s10096-019-03684-y. Epub 2019 Aug 28.
10
Update: Influenza Activity - United States and Worldwide, May 20-October 13, 2018.更新：2018 年 5 月 20 日至 10 月 13 日美国和全球的流感活动。
MMWR Morb Mortal Wkly Rep. 2018 Oct 26;67(42):1178-1185. doi: 10.15585/mmwr.mm6742a3.

本文引用的文献

1
ACP Journal Club. Review: Neuraminidase inhibitors relieve influenza symptoms and reduce laboratory-confirmed influenza in healthy adults.《美国内科医师学会杂志俱乐部》。综述：神经氨酸酶抑制剂可缓解健康成年人的流感症状并减少实验室确诊的流感病例。
Ann Intern Med. 2010 Feb 16;152(4):JC-211. doi: 10.7326/0003-4819-152-4-201002160-02011.
2
Complications: tracking down the data on oseltamivir.并发症：追查关于奥司他韦的数据。
BMJ. 2009 Dec 8;339:b5387. doi: 10.1136/bmj.b5387.
3
Why don't we have all the evidence on oseltamivir?为什么我们没有关于奥司他韦的所有证据？
BMJ. 2009 Dec 8;339:b5351. doi: 10.1136/bmj.b5351.
4
Neuraminidase inhibitors--the story behind the Cochrane review.神经氨酸酶抑制剂——Cochrane系统评价背后的故事
BMJ. 2009 Dec 8;339:b5164. doi: 10.1136/bmj.b5164.
5
Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis.用于预防和治疗健康成年人流感的神经氨酸酶抑制剂：系统评价与荟萃分析
BMJ. 2009 Dec 8;339:b5106. doi: 10.1136/bmj.b5106.
6
Influenza will not miss opportunities.流感不会错失机会。
Clin Infect Dis. 2006 Dec 15;43(12):1562-4. doi: 10.1086/508781. Epub 2006 Nov 8.
7
Safety and pharmacology of oseltamivir in clinical use.临床使用中奥司他韦的安全性与药理学
Drug Saf. 2003;26(11):787-801. doi: 10.2165/00002018-200326110-00004.
8
Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.奥司他韦治疗对流感相关下呼吸道并发症及住院情况的影响。
Arch Intern Med. 2003 Jul 28;163(14):1667-72. doi: 10.1001/archinte.163.14.1667.
9
[Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza--placebo-controlled double-blind multicenter phase III trial].选择性口服神经氨酸酶抑制剂奥司他韦治疗急性流感的临床疗效与安全性——安慰剂对照双盲多中心III期试验
Kansenshogaku Zasshi. 2000 Dec;74(12):1044-61. doi: 10.11150/kansenshogakuzasshi1970.74.1044.
10
HEpiMA: software for the identification of heterogeneity in meta-analysis.HEpiMA：用于识别荟萃分析中异质性的软件。
Comput Methods Programs Biomed. 2001 Feb;64(2):101-107. doi: 10.1016/s0169-2607(00)00087-0.